

Citibank N.A.
Securities Services
FIFC, 09th Floor,
C-54 & C-55, G-Block,
Bandra Kurla Complex,
Bandra (East)
Mumbai – 400 098, India

T +91 22 6175 7999 / 4502 7999
F +91 22 2653 2348



Dated: 30th-Jan-2025

**To,
The C.R.D,
Bombay Stock Exchange,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001**

Reporting under Substantial Acquisition of Shares and Take over Regulations, 2011 of Securities & Exchange Board of India (“SEBI”)

Dear Sir,

We on behalf of and as authorized representatives of our below mentioned client wish to make the necessary disclosures as required under the Substantial Acquisition of Shares and Take over Regulations, 2011 of Securities & Exchange Board of India (“SEBI”)

Please find below the relevant details in this regard for your ready reference. In this connection, we have also enclosed herewith the necessary disclosure forms.

Name of the acquirer & PAC with the acquirer	TIMF HOLDINGS TIMF HOLDINGS FDI THINK INDIA OPPORTUNITIES MASTER FUND LP THINK INDIA OPPORTUNITIES MASTER FUND LP FDI THINK INVESTMENTS PCC THINK INVESTMENTS PCC FDI
SEBI Registration No.	IN-MU-FP-0009-14 IN-CY-FP-0461-20 IN-MU-FP-0654-22
Scrip	ONESOURCE SPECIALTY PHARMA LIMITED
Total Holdings (No. of Shares)	5,906,965
Paid Up Equity Capital (No. of Shares)	114,436,021
Current % Holding	5.16 %

In view of the aforesaid, you are requested to take this on records and do the needful. For any further queries in this regard, please contact us on 91-22-6175 6960.

Thanking You,

Truly Yours,
By Constituted Attorney

Nagesh Kini
Enclosures: As above.

ANNEXURE A			
Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011			
Part-A- Details of the Acquisition			
Name of the Target Company (TC)	ONESOURCE SPECIALTY PHARMA LIMITED		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	TIMF HOLDINGS TIMF HOLDINGS FDI THINK INDIA OPPORTUNITIES MASTER FUND LP THINK INDIA OPPORTUNITIES MASTER FUND LP FDI THINK INVESTMENTS PCC THINK INVESTMENTS PCC FDI		
Whether the acquirer belongs to Promoter/Promoter group	NO		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE & NSE		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
<u>Before the acquisition under consideration, holding of</u>			
a) Shares carrying voting rights	0	0.00%	0.00%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c)	0	0.00%	0.00%
<u>Details of acquisition</u>			
a) Shares carrying voting rights acquired	5,906,965	5.16%	5.16%
b) VRs acquired otherwise than by equity shares			

c) Warrants/convertible securities/any other instrument			
d) Shares in the nature of encumbrance (pledge/ lien/non-			
e) Total (a+b+c+/-d)	5,906,965	5.16%	5.16%
After the acquisition, holding of acquirer along with PACs of:			
a) Shares in the nature of encumbrance (pledge/ lien/non-	5,906,965	5.16%	5.16%
b) VRs otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument			
d) Total (a+b+c)	5,906,965	5.16%	5.16%
LISTING OF SECURITY			
Mode of acquisition (e.g. open market / public issue / rights			
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity			
Date of acquisition of/ date of receipt of intimation of	24-Jan-2025		
Equity share capital / total voting capital of the TC before	0	(shs)	
Equity share capital/ total voting capital of the TC after the	114,436,021	(shs)	
Total diluted share/voting capital of the TC after the said	114,436,021	(shs)	
Part-B***			
Name of the Target Company: ONESOURCE SPECIALTY PHARMA LIMITED			

Signature of the acquirer / Authorised Signatory

Place: Mumbai

Date:30-Jan-2025

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.